NASDAQ: REVB
Revelation Biosciences, Inc.
Healthcare · Biotechnology
Market Cap
$3.83M
52w High
$12.88
52w Low
$0.88
P/E
-0.32
Volume
66.06K
Outstanding Shares
3.91M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 89.71% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow grew 52.06% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive move in revenue — currently down 100% — would be the clearest signal to resolve the ambiguity.
Company profile
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system.
Valuation
Stock splits
Every 4 shares became 1
Every 3 shares became 1
Every 16 shares became 1
Every 30 shares became 1
Every 35 shares became 1
Profitability & growth
Analyst consensus
2
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 7, 2026
Q3 FY26 · EPS est -$0.83 · Revenue est —
View